NCT04780321View on ClinicalTrials.gov

JS016 (Anti-SARS-CoV-2 Monoclonal Antibody)With Mild and Moderate COVID-19 or SARS-CoV-2 Asymptomatic Infection Subects

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

October 30, 2020

Primary Completion Date

August 31, 2021

Study Completion Date

August 31, 2021

Conditions
COVID-19
Interventions
BIOLOGICAL

Recombinant Human Anti-SARS-CoV-2 Monoclonal Antibody(25mg/kg;50mg/kg;100mg/kg)

use dose 1/2/3 60 patients receipt JS016 intravenous infusion on day 1

DRUG

Placebo

30 patients receipt placebo intravenous infusion on day 1

Trial Locations (2)

100010

Beijing Ditan Hospital affiliated to Capital Medical University, Beijing

Unknown

Huashan Hospital affiliated to Fudan University, Shanghai

All Listed Sponsors
lead

Shanghai Junshi Bioscience Co., Ltd.

OTHER

NCT04780321 - JS016 (Anti-SARS-CoV-2 Monoclonal Antibody)With Mild and Moderate COVID-19 or SARS-CoV-2 Asymptomatic Infection Subects | Biotech Hunter | Biotech Hunter